[go: up one dir, main page]

WO2010020799A3 - Compositions for the treatment of neoplastic diseases - Google Patents

Compositions for the treatment of neoplastic diseases Download PDF

Info

Publication number
WO2010020799A3
WO2010020799A3 PCT/GB2009/002068 GB2009002068W WO2010020799A3 WO 2010020799 A3 WO2010020799 A3 WO 2010020799A3 GB 2009002068 W GB2009002068 W GB 2009002068W WO 2010020799 A3 WO2010020799 A3 WO 2010020799A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
neoplastic diseases
taxane
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/002068
Other languages
French (fr)
Other versions
WO2010020799A2 (en
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Johannes Moes
Bastiaan Nuijen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Original Assignee
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Application filed by Netherlands Cancer Institute, SLOTERVAART PARTICIPATIES BV filed Critical Netherlands Cancer Institute
Priority to EP09785003A priority Critical patent/EP2328555A2/en
Priority to JP2011523454A priority patent/JP2012500788A/en
Priority to US13/060,037 priority patent/US20110207804A1/en
Publication of WO2010020799A2 publication Critical patent/WO2010020799A2/en
Publication of WO2010020799A3 publication Critical patent/WO2010020799A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant, wherein the substantially amorphous taxane is prepared by a solvent evaporation method and, in particular, spray drying. Methods of preparation of the composition and uses of the composition are also included.
PCT/GB2009/002068 2007-08-24 2009-08-24 Composition Ceased WO2010020799A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09785003A EP2328555A2 (en) 2008-08-22 2009-08-24 Compositions for the treatment of neoplastic diseases
JP2011523454A JP2012500788A (en) 2008-08-22 2009-08-24 Composition
US13/060,037 US20110207804A1 (en) 2007-08-24 2009-08-24 Compositions for the treatment of neoplastic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBPCT/GB2008/002854 2008-08-22
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (2)

Publication Number Publication Date
WO2010020799A2 WO2010020799A2 (en) 2010-02-25
WO2010020799A3 true WO2010020799A3 (en) 2010-10-14

Family

ID=41229935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002068 Ceased WO2010020799A2 (en) 2007-08-24 2009-08-24 Composition

Country Status (3)

Country Link
EP (1) EP2328555A2 (en)
JP (1) JP2012500788A (en)
WO (1) WO2010020799A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089544B2 (en) 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2525783A1 (en) * 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CA3124316C (en) 2018-12-21 2023-07-04 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels
EP3897611A1 (en) 2018-12-21 2021-10-27 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
EP4385507A1 (en) 2022-12-13 2024-06-19 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041896A1 (en) * 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20020082291A1 (en) * 1999-01-13 2002-06-27 Marie-Christine Bissery New use of taxoid derivatives
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
US20040167139A1 (en) * 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883477B1 (en) * 1999-05-27 2009-02-16 아쿠스피어 인코포레이티드. Pharmaceutical composition of porous drug matrix
KR100508518B1 (en) * 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082291A1 (en) * 1999-01-13 2002-06-27 Marie-Christine Bissery New use of taxoid derivatives
US20020041896A1 (en) * 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20040167139A1 (en) * 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same

Also Published As

Publication number Publication date
JP2012500788A (en) 2012-01-12
EP2328555A2 (en) 2011-06-08
WO2010020799A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2008006715A3 (en) Improvements relating to pharmaceutical compositions
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2009027644A3 (en) Compositions for the treatment of neoplastic diseases
WO2011014850A3 (en) Topical eutectic-based formulations
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2007109605A3 (en) Pharmaceutical compositions
WO2011063990A8 (en) Spider silk particles for controlled and sustained delivery of compounds
WO2009021986A8 (en) Seed treatment compositions and methods
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2010072958A3 (en) Topical pharmaceutical composition containing a water-sensitive active principle
WO2008006795A3 (en) Indole compounds
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
HK1211924A1 (en) Solid forms of an antiviral compound
WO2012161497A3 (en) Peptide derivatives having a superior moisturizing effect and uses thereof
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2010044585A3 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2012007225A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue.
WO2009094457A3 (en) Substituted benzhydrylethers
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785003

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011523454

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009785003

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13060037

Country of ref document: US